Novartis Would Get Anti-Infective, Oncologic Pipeline Drugs In Chiron Deal
Executive Summary
Novartis' proposed acquisition of Chiron would give the company anti-cancer and anti-infective molecules to complement its oncologic portfolio and infectious disease pipeline